Jeff Jones
Stock Analyst at Oppenheimer
(3.85)
# 648
Out of 5,154 analysts
88
Total ratings
30%
Success rate
18.68%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $23.43 | +113.40% | 4 | Mar 6, 2026 | |
| PTHS Pelthos Therapeutics | Maintains: Outperform | $57 → $60 | $23.12 | +159.52% | 3 | Jan 26, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $15 → $32 | $15.80 | +102.60% | 6 | Jan 21, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $83.49 | +43.73% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.88 | +1,229.79% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $8.01 | +561.67% | 10 | Aug 6, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $26.90 | -7.06% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $6.97 | +143.90% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.97 | +160.84% | 2 | May 8, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $3.17 | +467.82% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.77 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.97 | +221.93% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.33 | +3,283.46% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.13 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $2.85 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.80 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.64 | +814.63% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.08 | +90,044.23% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.18 | +34,491.19% | 2 | Nov 17, 2022 |
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $23.43
Upside: +113.40%
Pelthos Therapeutics
Jan 26, 2026
Maintains: Outperform
Price Target: $57 → $60
Current: $23.12
Upside: +159.52%
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Outperform
Price Target: $15 → $32
Current: $15.80
Upside: +102.60%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $83.49
Upside: +43.73%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.88
Upside: +1,229.79%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $8.01
Upside: +561.67%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $26.90
Upside: -7.06%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $6.97
Upside: +143.90%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.97
Upside: +160.84%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.17
Upside: +467.82%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.77
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.97
Upside: +221.93%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.33
Upside: +3,283.46%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $9.13
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.85
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.80
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.64
Upside: +814.63%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.08
Upside: +90,044.23%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.18
Upside: +34,491.19%